TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05047484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Powder-in-capsule (PIC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Powder-in-capsule (PIC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Powder-in-capsule (PIC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Powder-in-capsule (PIC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Powder-in-capsule (PIC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Powder-in-capsule (PIC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PIC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PIC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PIC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PIC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PIC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PIC.
Study: NCT00700050

Intervention type: DRUG
Intervention: Hypertonic saline
Description: Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.

Intervention type: DRUG
Intervention: Hypertonic saline
Description: Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.

Intervention type: DRUG
Intervention: Hypertonic saline
Description: Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.

Intervention type: DRUG
Intervention: Hypertonic saline
Description: Subjects will be asked to expectorate sputum samples. If necessary to achieve this, subjects will inhale wet-nebulized 3% saline for up to 7 minutes each for up to 3 cycles.
Study: NCT03202732

Intervention type: OTHER
Group type: OTHER
Intervention: DiabetesFlex
Description: DiabetesFlex consist of one mandatory and two optional consultations. Before the consultations patients receive the AmbuFlex Diabetes questionnaire.~The AmbuFlex Diabetes questionnaire is based on both validated questionnaires and clinical consensus. The AmbuFlex Diabetes questionnaire consists of: SF36 well-being question, WHO-5 Well-being Index. Questions concerning: HgA1c, home-based blood pressure monitoring, incidents of hypoglycemia, diabetes complications, regular eye check, regular food check, erectile dysfunction and peripheral neuropathy, The PAID scale, Topics patients may want to talk with the health care professional about, the patient's evaluation of the need for diabetes care. View the AmbuFlex Diabetes questionnaire at the homepage: www.diabetesflex.auh.dk.
Study: NCT02028962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Study: NCT04121767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: oral edoxaban 60mg once daily for 3 months
Study: NCT01140282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Administered within 3 days of baseline testing and at post-trial visit

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Administered within 3 days of baseline testing and at post-trial visit

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Administered within 3 days of baseline testing and at post-trial visit

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: management of therapy complications
Description: Assessed within 3 days of baseline testing and at post-trial visit

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Assessed within 3 days of baseline testing and at post-trial visit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: 12 week exercise intervention
Study: NCT04550559

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ureterolitotripsy
Description: Endoscopic ureterolithotripsy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic ureterolitotripsy
Description: Endoscopic ureterolithotripsy
Study: NCT05080205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Roux-en-Y gastric bypass or sleeve gastrectomy, chosen based on routine evaluation process
Study: NCT00621192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: meropenem
Description: Meropenem was administered concomitantly with compatible medications. Because an in-line filter is not appropriate due to drug binding, the 30 minute infusion was rate controlled by using appropriate infusion (syringe) pumps. Dosing and administration of other antimicrobial therapy (e.g., an aminoglycoside) was administered per local standard of care at the discretion of the infant's neonatologist. If there was a delay in the study drug shipment, sites were to use open-label meropenem to protect the safety of the participant.~20 mg/kg every 12 hours in infants \<32 weeks GA and PNA \< 2 weeks 20 mg/kg every 8 hours in infants \<32 weeks GA and PNA ≥ 2 weeks 20 mg/kg every 8 hours in infants ≥32 weeks GA and PNA \< 2 weeks 30 mg/kg every 8 hours in infants ≥32 weeks GA and PNA ≥ 2 weeks
Study: NCT02754193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate hypothermia
Description: moderate hypothermia will be induced using the heat controller of the VA-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 24 hours ± 1h followed by a progressive reheating (0.2±0.1°C/h) to reach 37 °C. Temperature at 37°C ± 0.3°C will be maintained during 48 hours ± 4h after having reached 37 °C.
Study: NCT04444219

Intervention type: OTHER
Group type: OTHER
Intervention: Breakfast meals
Description: Fifteen volunteers will undergo a medical and dietary assessment and their health status will be evaluated through a complete blood count. Then, they will come after overnight fasting and will consume one of two breakfast meals, including 114g bread, 40g cheese and 15g dry mushrooms (meal 1) or 114g bread, 40g cheese and 200g tomatoes (meal 2). Blood samples will be obtained on timepoints 0h, 30min, 1h, 1,5h, 2h, 2,5h and 3h after breakfast intake. Two weeks later, the same volunteers will consume the other breakfast meal.

Intervention type: OTHER
Group type: OTHER
Intervention: Breakfast meals
Description: Fifteen volunteers will undergo a medical and dietary assessment and their health status will be evaluated through a complete blood count. Then, they will come after overnight fasting and will consume one of two breakfast meals, including 114g bread, 40g cheese and 15g dry mushrooms (meal 1) or 114g bread, 40g cheese and 200g tomatoes (meal 2). Blood samples will be obtained on timepoints 0h, 30min, 1h, 1,5h, 2h, 2,5h and 3h after breakfast intake. Two weeks later, the same volunteers will consume the other breakfast meal.
Study: NCT03654768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosutinib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04121767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: oral warfarin once daily for 3 months according to prothrombin time
Study: NCT03654768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Given PO
Study: NCT03903497

Intervention type: DEVICE
Group type: OTHER
Intervention: NBI
Description: optical assessment of diminutive colorectal polyps by NBI mode using the WASP assessment
Study: NCT02087215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: boron gel
Description: application of a formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v) to diabetic foot ulcers.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04692545

Intervention type: DIETARY_SUPPLEMENT
Intervention: Immunonutrition
Description: nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
Study: NCT00166881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-Irinotecan
Description: Docetaxel-Irinotecan, weekly, days 1, 8, 15, repeated every 4 weeks
Study: NCT02635386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (EQW )
Description: 2 mg SC injection every 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (DAPA)
Description: One pill (10 mg) by mouth daily (QD) in am

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EQW plus DAPA
Description: 2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin plus Glucophage (MET ER)
Description: DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine /Topiramate (PHEN/ TPM) ER
Description: PHEN 3.75/TPM ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TPM ER 46mg- 1 pill by mouth once daily in am
Study: NCT01776008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Therapy
Description: Given before standard-care surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard-care surgery
Study: NCT01993641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pracinostat
Description: Histone deacetylase inhibitor (HDACi) Pracinostat is to be taken before HMA administration 3 times/week (e.g., Monday, Wednesday, and Friday) for 3 weeks, followed by 1 week of rest as a 28-day cycle. Pracinostat administration will be at the clinic on Day 1 of Cycles 1 and 2 and subject will self-administer at home on all other days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: All patients will receive the dose and schedule of azacitadine to which they previously failed to respond. (e.g. 75 mg/m2 via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable; 7 days of each 28 day cycle, either Days 1-7, or Days 1-5, rest on Days 6-7, and azacitadine dosing on Days 8-9)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: All patients will receive the dose and schedule of decitabine to which they previously failed to respond. Common 28 day treatment regimens include: 20 mg/m2 IV for either 5 or 10 days of each 28-day cycle, 10 mg/m2 given intravenously daily for first 10 days of each 28 day cycle, or 20 mg/m2 given subcutaneously daily for the first 5 days of each 28 day cycle.~The 6-week regimen utilizes a dose of 15 mg/m2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days repeated every 6 weeks.
Study: NCT02175329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM Veneering
Description: CAD/CAM fabricated zirconia bridge framework is veneered with CAD/CAM fabricated lithium disilicate ceramic veneer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manually layered veneering
Study: NCT03183479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate Human
Description: After start of surgery when all pedicle screws are placed, the patients in treatment group will receive fibrinogen concentrate 30mg kg-1. For safety concern, functional fibrinogen will be measured and the maximum fibrinogen concentrate administration for each individual shall not exceed 2g. Fibrinogen concentrate will be diluted in 100mL of sterile water and then be administered to patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 100mL normal saline will be administered to patients in control group as placebo
Study: NCT02282163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulphur hexafluoride lipid-type A microspheres
Description: Ultrasound imaging contrast agent
Study: NCT04302129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: 20 ml local anaesthetic are injected bilaterally on each side of the surgical incision underneath the erector spinae muscle where the dorsal rami pass around the bases of the transverse processes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal analgesia
Description: Ketorolac 0.75 mg/ Kg and paracetamol 10 mg/ Kg intravenously
Study: NCT01971281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100L
Description: Patients will be treated continuously with the NovoTTF-100L. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100L
Description: Patients will be treated continuously with the NovoTTF-100L. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week rest from treatment. Subsequent cycles will consist of once weekly infusions days 1, 8, 15 every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week rest from treatment. Subsequent cycles will consist of once weekly infusions days 1, 8, 15 every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on days 1, 8 and 15 of each 28-day cycle.
Study: NCT01711398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug
Study: NCT01560195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated rhG-CSF: 100µg/kg
Description: Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated rhG-CSF: 6mg
Description: Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo and rhG-CSF 5ug/kg/d
Description: Patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF 5ug/kg/d in cycle 2 to 4. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
Study: NCT04805450

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ES before fully covered SEMS placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no ES before fully covered SEMS placement
Study: NCT01699308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genotropin
Study: NCT00312052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5555
Description: 50 mg or 100 mg E5555 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E5555
Description: 50 mg or 100 mg E5555 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5555
Description: 50 mg or 100 mg E5555 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 50 mg and/or 100 mg placebo tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 50 mg and/or 100 mg placebo tablets
Study: NCT00745498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml)
Study: NCT04962373

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Each participant will attend a 30-60 minute semi-structured interview conducted by the CI

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Each participant will attend a 30-60 minute semi-structured interview conducted by the CI

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Each participant will attend a 30-60 minute semi-structured interview conducted by the CI
Study: NCT01367444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR422459
Description: Pharmaceutical form: sterile solution, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR422459
Description: Pharmaceutical form: sterile solution, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR422459
Description: Pharmaceutical form: sterile solution, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection
Study: NCT04378374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-1
Description: Baked food made of lentil flour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-2
Description: Baked food made of lentil flour and wheat flour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-3
Description: Baked food made of wheat flour

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-4
Description: Potable water (energy and carbohydrate-free control)
Study: NCT03754790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fitusiran
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study: NCT01372007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120mg
Description: Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are \<10%, study medication (0.246mg lanreotide base/mg solution) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are \<10%, placebo (Sodiumchloride 0,9% 1 ampoule) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
Study: NCT01314599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion
Description: PM01183 Drug Product will be provided as a lyophilized powder for concentrate for solution for infusion with a strength of 1.0 mg/vial and 4.0 mg/vial.~Before use, the vials will be reconstituted with 2 ml or 8 ml of sterile water for injection to give a solution containing 0.5 mg/ml of PM01183.
Study: NCT01163474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluate video clinic visit prior to Face-to-Face usual care visit
Description: Evaluate video clinic visit prior to Face-to-Face usual care visit
Study: NCT00943046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker therapy
Description: Implantation of the SIELLO pacemaker leads
Study: NCT00827554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMWH
Description: Nadroparin Ca 4100 AXa iu twice daily lasted for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMWH
Description: Nadroparin Ca 4100 AXa iu twice daily lasted for 6 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: transarterial chemoembolization with lipiodol 1-1.5ml/cm tumor diametres，pharmorubicin 20mg，5-Fu 1g and Carboplatin 150mg。

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: transarterial chemoembolization with lipiodol 1-1.5ml/cm tumor diametres，pharmorubicin 20mg，5-Fu 1g and Carboplatin 150mg。
Study: NCT04374786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calm Meditation App
Description: Meditation is a self-management strategy that can be utilized by anyone to assist with the management of stress. Meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time.
Study: NCT02493842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transverse Intrafasicular Multichannel electrode (TIME)
Description: Peripheral nerve stimulation is conducted with Transverse Intrafasicular Multichannel electrode (TIME) version 4 electrodes to induce sensory sensations from the phantom hand, while subject is virtualizing a movement or event which may cause the specific sensation.